Tumor necrosis factor-α rs361525 polymorphism is associated with increased local production and downstream inflammation in chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 2, 2010, Pages 192-199

  Sapey, Elizabeth ^a   Wood, Alice M ^a   Ahmad, Ali ^b   Stockley, Robert A ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Inflammation; Obstructive lung disease; Physiological decline; Polymorphism

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 8; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; PEROXIDASE;

ADULT; AGED; ARTICLE; BODY MASS; CELL MIGRATION; CHEMOKINESIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; EPITHELIUM CELL; FEMALE; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; MALE; MEDIATOR RELEASE; NEUTROPHIL CHEMOTAXIS; PNEUMONIA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPUTUM ANALYSIS; BRONCHITIS; BRONCHUS; CASE CONTROL STUDY; CELL MOTION; CYTOLOGY; DISEASE COURSE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HOSPITALIZATION; METABOLISM; MIDDLE AGED; NEUTROPHIL; PHENOTYPE; PHYSIOLOGY; SECRETION; SPUTUM;

ADULT; AGED; BODY MASS INDEX; BRONCHI; BRONCHITIS; CASE-CONTROL STUDIES; CELL MOVEMENT; DISEASE PROGRESSION; EPITHELIAL CELLS; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMANS; INTERLEUKIN-8; MALE; MIDDLE AGED; NEUTROPHILS; PEROXIDASE; PHENOTYPE; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SPUTUM; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956620618     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200912-1846OC     Document Type: Article

References (61)

1. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989;245:1066-1073. (Pubitemid 19231814)
2. Jeppsson JO. Amino acid substitution glu-lys in alpha 1 antitrypsin piz. FEBS Lett 1976;65:195-197.
3. Hacievliyagil SS, Gunen H, Mutlu LC, Karabulet AB, Temel I. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. Respir Med 2006;100:846-854.
4. Kuschner WG, D'Alessandro A, Wong H, Blanc PD. Dose dependent cigarette smoking-related inflammatory changes in healthy adults. Eur Respir J 1996;9:1989-1994.
5. Sapey E, Ahmad A, Bayley D, Newbold P, Snell N, Rugman P, Stockley RA. Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. J Clin Immunol 2009;29:508-516.
6. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales RE. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349-355.
7. Di Francia M, Barbier D, Mege JL, Orehek J. Tumour necrosis factor alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453-1455.
8. Calikoglu M, Sahin G, Unlu A, Ozturk C, Tamer L, Ercan B, Kanik A, Atik U. Leptin and TNF alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters. Respiration 2004;71:45-50.
9. Nguyen LT, Bedu M, Caillaud D, Beaufrere B, Beaujon G, Vasson M, Coudert J, Ritz P. Increased resting energy expenditure is related to plasma TNF alpha concentration in stable COPD patients. Clin Nutr 1999;18:269-274.
10. Vuillemenot BR, Rodriguez JF, Hoyle GW. Lymphoid tissue and emphysema in the lungs of transgenic mice inducibly expressing TNF alpha. Am J Respir Crit Care Med 2004;30:438-448.
11. Wright JL, Tai H, Wang R, Wang X, Churg A. Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF alpha signaling. Am J Physiol Lung Cell Mol Physiol 2007;292:L125-L133.
12. Churg A,Wang RD, Tai H,Wang X, Xie C,Wright JL. Tumour necrosis factor alpha drives 70% of cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2004;170:492-498.
13. Lucey EC, Keane J, Kuang PP, Snider GL, Goldstein RH. Severity of elastase induced emphysema decreased in TNF alpha and IL-1 beta receptor deficient mice. Lab Invest 2002;82:79-85.
14. Rennard SI, Fogarty C, Kelson S, Long W, Ramsdell J, Allison J, Mahler D, Saadeh C, Siler T, Snell P, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926-934.
15. Wood AM, Gough SC, Stockley RA. Sputum TNFA levels are associated with TNFA genotype [abstract]. Am J Respir Crit Care Med 2009;179:A2942.
16. Wood AM, Simmonds MJ, Bayley DL, Newby PR, Gough SC, Stockley RA. The TNF alpha gene relates to clinical phenotype in alpha-1-antitryspin deficiency. Respir Res 2008;9:52-57.
17. Gingo MR, Silveira LJ, Miller YE, Friedlander AL, Cosgrove GP, Chan ED, Maier LA, Bowler RP. Tumour necrosis factor polymorphisms are associated with COPD. Eur Respir J 2008;31:1005-1012.
18. Higham MA, Pride NB, Alikhan A, Morrell NW. Tumour necrosis factor alpha gene promotor polymorphism in chronic obstructive pulmonary disease. Eur Respir J 2000;21:444-449.
19. Ferrarotti I, Zorzetto M, Beccaria M, Gile LS, Porta R, Ambrosino N, Pignatti, P.F., Cerveri, I, Pozzi, E., Luiseeti, M. Tumour necrosis factor family genes in a phenotype of COPD associated with emphysema. Eur Respir J 2003;21:444-449.
20. Hersh CP, Demeo DL, Lange C, Litonjua AA, Reilly JJ, Kwiatowski D. Attempted replication of reported chronic obstructive pulmonary disease candidate gene associations. Am J Respir Cell Mol Biol 2005;33:71-78.
21. Castaldi PJ, Cho MH, Cohn M, Langerman F, Moran S, Tarragona N, Moukhachen H, Venugopal R, Hasimja D, Kao E, et al. The COPD genetc association compendium: a comprehensive online database of COPD genetic associations. Hum Mol Genet 2010;19:526-534.
22. Simmonds MJ, Heward JM, Howson JMM, Foxall H, Nithiyananthan R, Franklyn JA, Gough SCL. A systematic approach to the assessment of known TNF alpha polymorphisms in graves disease. Genes Immun 2004;5:267-273.
23. NCBI SNP database. Accessed January 2010. Available from: www.ncbi.nlm.gov/projects/SNP/spr-ref.cgi.. 2010 Accessed January 2010.
24. Bayley JP, Ottenhoff THM, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun 2004;5:315-329.
25. Sapey E, Wood AM, Ahmad A, Griffith D, Edgar E, Stockley RA. Imbalances in TNF in patients with a TNF polymorphism and a COPD phenotype. Eur Respir J 2009;81:850.
26. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, Committee GS. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276.
27. Sapey E, Bayley D, Ahmad A, Stockley RA. The validation of assays used to measure biomarkers in exhaled breath condensate. Eur Respir J 2008;32:1408-1409.
28. Woolhouse IS, Bayley DL, Stockley RA. Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis. Thorax 2002;57:667-671.
29. Stockley RA, Bayley D. Validation of assays for inflammatory mediators in sputum. Eur Respir J 2000;15:778-781.
30. Gompertz S, Bayley D, Hill SL, Stockley RA. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001;56:36-41.
31. Gompertz S, O'Brien C, Bayley D, Hill SL, Stockley RA. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur Respir J 2001;17:1112-1119.
32. Mikami M, Llewellyn-Jones CG, Bayley D, Stockley RA. The chemotactic activity of sputum from patients with bronchiectasis. Am J Respir Crit Care Med 1998;157:723-728.
33. Zicha D, Dunn GA, Brown AF. A new direct-viewing chemotaxis chamber. J Cell Sci 1991;99:769-775.
34. Andrew N, Insall R. Chemotaxis in shallow gradients is mediated independently of ptdins-3-kinase by biased choices bewteen random protrusions. Nat Cell Biol 2007;9:193-200.
35. Bayley JP, de Rooij H, van den Elsen PJ, Huizinga TW, Verweij CL. Functional analysis of linker-scan mutants spanning the -376, -308, -244 and -238 polymorphic sites of the TNF alpha promoter. Cytokine 2001;14:316-323.
36. Do V, Tsuneto LT, Sossai CR, Lieber SR, Marques SB, Vigorito AC, Aranha FJ, de Brito Eid KA, Oliveria GB, Miranda EC, et al. IL2 and TNFA gene polymorphisms and the risk of graft-versus-host disease after allogenic naematopoietic stem cell transplantation. Scand J Immunol 2007;66:703-710.
37. Nedoszytko B, Szczerkowski-Dobosz A, Zablotna M, Glen J, Rebala K, Roskiewicz J. Associations of promoter region polymorphism in the tumour necrosis factor alpha gene and early onset psoriasis vulgaris in a northern Polish population. Br J Dermatol 2007;157:165-167.
38. Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, Chatterjee N, Yeager M, Chanock SJ, Rothman N. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-hodgkin lymphoma. Cancer Res 2006;66:9771-9780.
39. Sapey E, Bayley D, Ahmad A, Newbold P, Snell N, Stockley RA. Inter-relationships between inflammatory markers in stable COPD patients with bronchitis; the intra and inter patient variability. Thorax 2008;63:493-499.
40. Grell M, Wajant H, Zimmerman G, Scheurich P. The type 1 receptor is the high affinity receptor for soluble tumour necrosis factor. Proc Natl Acad Sci USA 1998;95:570-575.
41. Medvedev AE, Espevik T, Ranges G, Sundan A. Distinct roles of the two tumour necrosis factor (TNF) receptors in modulating TNF and lymphotoxin alpha effects. J Biol Chem 1996;271:9778-9784.
42. Beutler B, Milsark IW, Cerami A. Calchectin/tumour necrosis factor: production, distribution and metabolic fate in vivo. J Immunol 1985;135:3972-3977.
43. Johnston WW. The cytopathology of the respiratory tract: a review. Am J Pathol 1976;84:372-424.
44. Ahmad A, Bayley DL, He S, Stockley RA. Myeloid related protein 8/14 stimulates interleukin-8 production in airway epithelial cells. Am J Respir Cell Mol Biol 2003;29:523-530.
45. Woolhouse IS, Bayley D, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha 1 anti-trypsin deficiency and the role of leukotriene b4 and interleukin 8. Thorax 2002;57:709-714.
46. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002;121:151S-155S.
47. Smart SJ, Casale TB. TNF alpha induced transendothelial neutrophil migration is IL8 dependent. Am J Physiol 1994;266:L238-L245.
48. Liou TG, Campbell EJ. Quantum proteolysis resulting from release of single granules by human neutrophils: a novel, nonoxidative mechanism of extracellular proteolytic activity. J Immunol 1996;157:2624-2631.
49. Campbell EJ, Campbell MA, Boukedes SS, Owen CA. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1 anti trypsin deficiency. J Clin Invest 1999;104:337-344.
50. Cepinskas G, Sandig M, Kvietys PR. Paf induced elastase dependent neutrophil transendothelial migration is associated with the mobilisation of elastase to the neutrophil surface and localised to the migrating front. J Cell Sci 1999;112:1937-1945.
51. Niwa Y, Kasama T, Miyachi Y, Kanoh T. Neutrophil chemotaxis, phagocytosis and parameters of reactive oxygen species in human aging: cross sectional and longitudinal studies. Life Sci 1989;44:1655-1664.
52. Egger G, Aigner R, Glasner A, Hofer HP, Mitterhammer H, Zelzer S. Blood polymorphonuclear leukocyte migration as a predictive marker for infections in severe trauma: comparison with various inflammatory parameters. Intensive Care Med 2004;30:331-334.
53. Lauterbach M, O'Donnell P, Asano K, Mayadas T. Role of TNF priming and adhesion molcules in neutrophil recruitment to intravascular immune complexes. J Leukoc Biol 2008;83:1423-1430.
54. Sheppard FR, Kelher MR, Moore EE, McLaughlin MJ, Banerjee A, Silliman CC. Structural organizaton of the neutrophil naph oxidase: phosphorylation and translocation durng priming and activation. J Leukoc Biol 2005;78:1025-1042.
55. Ogilvie AC, Hack CE, Wagstaff J, van Mierlo GJ, Erenberg AJ, Thomsen LL, Hoekman K, Rankin EM. IL-1beta does not cause neutrophil degranulation but does lead to IL-6, IL-8 and nitrite/nitrate release when used in pateints with cancer. J Immunol 1996;156:389-394.
56. Berkow RL, Wang D, Larrick JW, Dodson RW, Howard TH. Enhancement of neutrophil superoxide production by pre-incubation with recombinant human tumour necrosis factor. J Immunol 1987;139:3788-3791.
57. Eiger A, Sinha B, Hartmann G, Endres S. Taming TNF: strategies to restrain this pro-inflammatory cytokine. Immunol Today 1997;18:487-492.
58. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, Beckett P, Al Ali M, Chauhan A, Wilson SJ, et al. Tumour necrosis factor as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60:1012-1018.
59. Morjaria JB, Chauhan A, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNF alpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double-blinded randomised placebo controlled trial. Thorax 2008;63:584-591.
60. Oliveria GB, Polosa R. Etanercept in chronic severe asthma. Thorax 2006;61:640.
61. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen city heart study group. Am J Respir Crit Care Med 1996;153:1530-1535.